argenx reported its half-year 2025 financial results and provided a second-quarter business update, highlighting Vyvgart sales of $949 million for Q2 2025, which exceeded consensus estimates. This performance has driven argenx's annualized revenue run rate to approximately $4 billion. Following the report, argenx's stock surged 15.2% in pre-market trading. Additionally, several biotechnology companies including Sangamo Therapeutics, Agenus, CytomX Therapeutics, and Corvus Pharmaceuticals announced upcoming earnings calls or financial updates for the second quarter of 2025, with CytomX Therapeutics and Corvus Pharmaceuticals scheduled to report results on August 7, 2025.